Advanced in Lung Cancer

Prunella L. Blinman

Chris O'Brien Lifehouse, 119-143 Missenden Road, 
Camperdown, NSW, AU 
Advanced in Lung Cancer
Chris O'Brien Lifehouse, 119-143 Missenden Road, 
Camperdown, NSW, AU 
OverviewLocationsClinical Research

Overview

Prunella Blinman practices in Camperdown, Australia. Blinman is rated as an Advanced expert by MediFind in the treatment of Lung Cancer. Their top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Peripheral Neuropathy, Colorectal Cancer, and Nephrectomy.

Their clinical research consists of co-authoring 62 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 21 articles and participated in 1 clinical trial in the study of Lung Cancer.

Locations

Chris O'Brien Lifehouse, 119-143 Missenden Road, Camperdown, NSW 2050, Australia
Other Locations
Hospital Road, Concord, NSW, Australia
Hospital Road, Concord, NSW 2139, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

MesomiR 1: A Phase I Study of Intravenously Administered Epidermal Growth Factor Receptor -Targeted, EnGeneIC Delivery Vehicle (EDV)-Packaged, miR-16 Mimic (TargomiRs) for Patients With Malignant Pleural Mesothelioma (MPM) and Advanced Non-Small Cell Lung Cancer (NSCLC) Failing on Std Therapy
MesomiR 1: A Phase I Study of Intravenously Administered Epidermal Growth Factor Receptor -Targeted, EnGeneIC Delivery Vehicle (EDV)-Packaged, miR-16 Mimic (TargomiRs) for Patients With Malignant Pleural Mesothelioma (MPM) and Advanced Non-Small Cell Lung Cancer (NSCLC) Failing on Std Therapy
Enrollment Status: Completed
Publish Date: April 07, 2017
Intervention Type: Drug
Study Phase: Phase 1

60 Total Publications

Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis.
Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Blinman's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile